Clinical Trial of Safety and Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adults
Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adult Patients
Sponsor: Materia Medica Holding
This PHASE3 trial investigates Acute Upper Respiratory Tract Infections and is currently completed. Materia Medica Holding leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Jan 2018 [monthly]
Completed PHASE3
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Materia Medica Holding
For direct contact, visit the study record on ClinicalTrials.gov .